Your browser doesn't support javascript.
loading
IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.
Darwich, Adam S; Margolskee, Alison; Pepin, Xavier; Aarons, Leon; Galetin, Aleksandra; Rostami-Hodjegan, Amin; Carlert, Sara; Hammarberg, Maria; Hilgendorf, Constanze; Johansson, Pernilla; Karlsson, Eva; Murphy, Dónal; Tannergren, Christer; Thörn, Helena; Yasin, Mohammed; Mazuir, Florent; Nicolas, Olivier; Ramusovic, Sergej; Xu, Christine; Pathak, Shriram M; Korjamo, Timo; Laru, Johanna; Malkki, Jussi; Pappinen, Sari; Tuunainen, Johanna; Dressman, Jennifer; Hansmann, Simone; Kostewicz, Edmund; He, Handan; Heimbach, Tycho; Wu, Fan; Hoft, Carolin; Pang, Yan; Bolger, Michael B; Huehn, Eva; Lukacova, Viera; Mullin, James M; Szeto, Ke X; Costales, Chester; Lin, Jian; McAllister, Mark; Modi, Sweta; Rotter, Charles; Varma, Manthena; Wong, Mei; Mitra, Amitava; Bevernage, Jan; Biewenga, Jeike; Van Peer, Achiel; Lloyd, Richard.
Afiliación
  • Darwich AS; University of Manchester, United Kingdom.
  • Margolskee A; University of Manchester, United Kingdom. Electronic address: alison.margolskee@manchester.ac.uk.
  • Pepin X; AstraZeneca, United Kingdom; Sanofi, France.
  • Aarons L; University of Manchester, United Kingdom.
  • Galetin A; University of Manchester, United Kingdom.
  • Rostami-Hodjegan A; University of Manchester, United Kingdom; Simcyp Ltd, United Kingdom.
  • Carlert S; AstraZeneca, Sweden.
  • Hammarberg M; AstraZeneca, Sweden.
  • Hilgendorf C; AstraZeneca, Sweden.
  • Johansson P; AstraZeneca, Sweden.
  • Karlsson E; AstraZeneca, Sweden.
  • Murphy D; AstraZeneca, United Kingdom.
  • Tannergren C; AstraZeneca, Sweden.
  • Thörn H; AstraZeneca, Sweden.
  • Yasin M; AstraZeneca, United Kingdom.
  • Mazuir F; Sanofi, France.
  • Nicolas O; Sanofi, France.
  • Ramusovic S; Sanofi, Germany.
  • Xu C; Sanofi, United States.
  • Pathak SM; Simcyp Ltd, United Kingdom.
  • Korjamo T; Orion Pharma, Finland.
  • Laru J; AstraZeneca, United Kingdom; Orion Pharma, Finland.
  • Malkki J; Orion Pharma, Finland.
  • Pappinen S; Orion Pharma, Finland.
  • Tuunainen J; Orion Pharma, Finland.
  • Dressman J; Goethe University Frankfurt am Main, Germany.
  • Hansmann S; Goethe University Frankfurt am Main, Germany.
  • Kostewicz E; Goethe University Frankfurt am Main, Germany.
  • He H; Novartis, United States.
  • Heimbach T; Novartis, United States.
  • Wu F; Novartis, United States.
  • Hoft C; AbbVie, Germany.
  • Pang Y; AbbVie, Germany.
  • Bolger MB; Simulations Plus, Inc., United States.
  • Huehn E; Simulations Plus, Inc., United States.
  • Lukacova V; Simulations Plus, Inc., United States.
  • Mullin JM; Simulations Plus, Inc., United States.
  • Szeto KX; Simulations Plus, Inc., United States.
  • Costales C; Pfizer, United States.
  • Lin J; Pfizer, United States.
  • McAllister M; Pfizer, United Kingdom.
  • Modi S; Pfizer, United States.
  • Rotter C; Pfizer, United States.
  • Varma M; Pfizer, United Kingdom.
  • Wong M; Pfizer, United Kingdom.
  • Mitra A; Merck Sharp & Dohme (MSD), United Kingdom.
  • Bevernage J; Janssen, Belgium.
  • Biewenga J; Janssen, Belgium.
  • Van Peer A; Janssen, Belgium.
  • Lloyd R; GlaxoSmithKline, United Kingdom.
Eur J Pharm Sci ; 96: 626-642, 2017 Jan 01.
Article en En | MEDLINE | ID: mdl-27693299
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Biofarmacia / Simulación por Computador / Preparaciones Farmacéuticas / Modelos Biológicos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Pharm Sci Asunto de la revista: FARMACIA / FARMACOLOGIA / QUIMICA Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Biofarmacia / Simulación por Computador / Preparaciones Farmacéuticas / Modelos Biológicos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Pharm Sci Asunto de la revista: FARMACIA / FARMACOLOGIA / QUIMICA Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido